James Noble - 13 Feb 2025 Form 4 Insider Report for LAVA Therapeutics NV (LVTX)

Role
Director
Signature
/s/ Amy Garabedian, Attorney-in-Fact
Issuer symbol
LVTX
Transactions as of
13 Feb 2025
Net transactions value
$0
Form type
4
Filing time
18 Feb 2025, 20:15:20 UTC
Previous filing
02 Jan 2025
Next filing
17 Nov 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LVTX Common Shares (Right to Buy) Award $0 +33,390 $0.000000 33,390 13 Feb 2025 Common Shares 33,390 $0.9300 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares underlying the option will vest on February 13, 2026, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date.